Stay updated on BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer
Sign up to get notified when there's something new on the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page.

Latest updates to the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page
- Check5 days agoChange DetectedUpdate to Revision: v3.0.2 (replacing v3.0.1); removal of the Back to Top link. This signals a new release with potential fixes or improvements, while core content remains largely unchanged.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check19 days agoChange DetectedThe webpage has been updated to include new drug information for Nivolumab and Pazopanib, as well as additional details about clear-cell metastatic renal cell carcinoma. However, several previous entries related to drug classifications and genetic resources have been removed.SummaryDifference5%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
Stay in the know with updates to BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer
Enter your email address, and we'll notify you when there's something new on the BIONIKK Trial: Nivolumab vs VEGFR tKi in Kidney Cancer page.